Lung cancer in non-smokers is a biologically distinct disease from that in smokers, according to a new study. Researchers also found it has characteristics that mean it could be targeted with tailored treatments.

A personalised cancer vaccine, used in combination with an immunotherapy drug, triggers a response from the immune system that is specific to the cancer and shows some clinical benefit, according to the results of an early clinical trial presented at the virtual AACR conference.

Computer scientists working with pathologists have trained an artificial intelligence (AI) tool to determine which patients with lung cancer have a higher risk of their disease coming back after treatment.